AOP-208 / AOP Orphan Pharma, Leukos Biotech - LARVOL DELTA

Safety and pharmacokinetics of a novel, first-in-class HTR1B antagonist LB-208/AOP208 in patients with relapsed or refractory solid tumors or lymphoma: interim results from the first-in-human, phase 1 SERONCO-1 trial (ESMO 2026) - No abstract available

Clinical • First-in-human • P1 data • PK/PD data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

LB208-1-002: Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS (clinicaltrialsregister.eu) - P1/2 | N=60 | Not yet recruiting | Sponsor: Aop Orphan Pharmaceuticals GmbH

New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

SERONCO-1: First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphoma (clinicaltrialsregister.eu) - P1 | N=57 | Recruiting | Sponsor: Leukos Biotech S.L. | -> Recruiting | Phase classification: PN/A ➔ P1

Enrollment open • First-in-human • Phase classification • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

LB-208/AOP208 a first-in-class HTR1B antagonist: First-in-human, dose finding phase I study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity in adult patients with relapsed or refractory solid tumors or lymphoma (ESMO 2025) - "Clinical trial identification 2023-509532-25-00. Legal entity responsible for the study Leukos Biotech, S.L. Funding Leukos Biotech, S.L."

Clinical • First-in-human • P1 data • PK/PD data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results (Businesswire) - "SERONCO-1, a phase I, first-in-human trial in patients with solid tumors and lymphomas will be conducted in collaboration with Leukos Biotech at the Vall d’Hebron Institute of Oncology (VHIO) with partial funding from the Spanish Ministry of Science and Innovation through the Public-Private Partnership Program (CPP2021-008715). A subsequent trial in acute myeloid leukemia is expected to commence in 2026."

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology